CRANBURY, N.J., April 27, 2016 /PRNewswire/ -- Innophos Holdings, Inc. (NASDAQ: IPHS), today announced its financial results for the first quarter 2016.

Highlights


    --  Adjusted EBITDA of $31 million, in line with first quarter 2015, and up
        39% sequentially, resulting in a margin of 17%, up 90 basis points
        compared to the prior year quarter.
    --  Adjusted diluted EPS for the first quarter 2016 was $0.66 compared to an
        adjusted EPS of $0.64 for the first quarter 2015 and an adjusted EPS of
        $0.32 for the fourth quarter 2015.
    --  Restructuring and streamlining savings of $2.5 million in line with
        expectations.
    --  Innophos Nutrition plant closure at Paterson, NJ effective March 31(st).
    --  Han Kieftenbeld joins the company as Senior Vice President and Chief
        Financial Officer.
    --  Amy Hartzell joins the company as Vice President, Supply Chain and
        Purchasing.

Kim Ann Mink, Ph.D., Chief Executive Officer, commented, "In the first quarter, we began constructing a road map for the strategic direction of Innophos, while simultaneously identifying value creation levers that will drive sustainable improvement in the company's financial performance. While still early in our journey, I am pleased with the level of engagement across the entire organization. These initiatives will continue to be a core focus for us throughout 2016. While the market environment continues to pose challenges for our business, we generated adjusted EBITDA of $31 million, up significantly on a sequential basis. We are pleased to report this sequential improvement in our profitability and to see our cost management efforts begin to take effect during the quarter."

Dr. Mink continued, "Going forward, we are committed to making meaningful changes to drive operational excellence, commercial excellence and strategic growth, the three strategic pillars of our transformation. Underlying all three of these pillars is a foundation based on building a strong management team who brings deep industry, functional and change management experience. Accordingly, we have already begun this process with the recently announced hire of Han Kieftenbeld as Chief Financial Officer. I am also pleased to highlight the addition of Amy Hartzell, Vice President, Supply Chain and Purchasing to our management team. As we continue to execute on our strategic pillars, I am confident that Han and Amy's contributions will help support and enhance our transformation, creating strategic growth and delivering value for our shareholders. We are off to an excellent start to our journey and look forward to our future."

First Quarter Results


    --  Net sales for the first quarter 2016 of $190 million were down 6%
        compared to the first quarter 2015, and up 11% sequentially.
    --  Specialty Phosphates sales of $177 million were down 7% versus the prior
        year quarter, primarily due to lower volumes in the US/Canada segment,
        as selling prices were relatively flat overall. Sales increased 7%
        sequentially, on 2% higher prices and 5% higher volumes.
        --  US/Canada Specialty Phosphates sales of $137 million were down 7%
            compared to the prior year quarter, and up 8% sequentially. Selling
            prices increased 1% year over year, on improved customer mix, while
            volumes declined 8%, due to weak demand that carried into the early
            part of the quarter and reduced sales in lower margin, less
            differentiated applications.
        --  Mexico Specialty Phosphates sales of $40 million decreased 4%
            compared to the year ago period on 1% lower volumes and 3% lower
            prices, primarily in PPA, and increased 6% sequentially.
    --  GTSP & Other sales of $13 million were up 2% versus prior year quarter
        primarily on higher volumes, mostly offset by weaker fertilizer market
        prices. Sales were well up on a sequential basis.
    --  Adjusted EBITDA of $31 million was on par with prior year and up 39%
        sequentially.
    --  Adjusted diluted EPS for the first quarter 2016 was $0.66 compared to an
        adjusted EPS of $0.64 for the first quarter 2015 and an adjusted EPS of
        $0.32 for the fourth quarter 2015.
    --  Capital expenditures were $8 million in the first quarter 2016
        (approximately 75% maintenance, 25% growth).
    --  Net debt increased sequentially by $19 million in the first quarter
        2016, to $214 million, due to tax payments made in the United States
        after recognizing revenue received from foreign subsidiaries in the
        fourth quarter 2015 for United States income tax purposes. The related
        expenses pertaining to that revenue will be recognized for United States
        income tax purposes over the next two years.

Recent Trends and Outlook

Specialty Phosphates volumes are expected to decline by 3-5% for full year 2016 compared to 2015, primarily due to reduced sales in lower margin, less differentiated applications in the United States and detergent application reformulation that is expected to affect the Mexico Specialty Phosphates segment. Market demand in 2016 is expected to remain challenging in the United States and Canada home markets due to continued pressures on packaged foods.

Market phosphate rock prices declined approximately 12% in the first quarter 2016 versus the fourth quarter 2015, and sulfur market prices decreased 14% during the same period. Both are expected to ease further in the second quarter given current weak fertilizer market conditions. Cost improvements from the restructuring program implemented in the third quarter 2015 were in line with expectations, with $2.5 million lower costs realized in the current quarter against the third quarter 2015 baseline. Management continues to review cost actions and productivity initiatives given the challenging market conditions.

Adjusted EBITDA of $31 million for the first quarter 2016 yielded a margin of 17%, up 90 basis points compared to the prior year quarter. Adjusted EBITDA results for the second quarter are expected to be broadly in line with first quarter 2016 when considering the following effects:


    --  Continued headwinds in sales; seasonality expected to provide sequential
        improvement.
    --  Strength of US Dollar will continue to attract competition from overseas
        and pressure exports from the US.
    --  Some softening of raw material costs.
    --  Planned maintenance stoppage cost expected in the $4 million range.

2016 capital expenditures will approximate $40 million due to additional requirements to support strategic manufacturing initiatives and restructuring, along with continuous improvement in our plants.

Conference Call

Innophos will host its first quarter 2016 conference call on Thursday, April 28, 2016 at 10:00 am ET. The call can be accessed by dialing 1-888-771-4371 (U.S.) or 1-847-585-4405 (international) and entering passcode 42367604. Please dial in approximately 15 minutes ahead of the start time to ensure timely entry to the call. A replay will be available between 1:00 pm ET on April 28 and 11:00 pm ET on May 12, 2016. The replay is accessible by dialing 1-888-843-7419 (U.S.) or 1-630-652-3042 (international) and entering passcode 4236 7604#. Additional information on Innophos' first quarter results can also be found on the Company's website.

About the Company

Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico and China. For more information please visit www.innophos.com. 'IPHS-G'

Contact

Investors: Mark Feuerbach, 609-366-1204 or investor.relations@innophos.com

Media: Bryan Armstrong, FTI Consulting, Inc., 312-553-6707

Financial Tables Follow

Safe Harbor for Forward-Looking and Cautionary Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. As such, final results could differ from estimates or expectations due to risks and uncertainties, including but not limited to: incomplete or preliminary information; changes in government regulations and policies; continued acceptance of Innophos' products and services in the marketplace; competitive factors; technological changes; Innophos' dependence upon suppliers; and other risks. For any of these factors, Innophos claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended.

Summary Profit & Loss Statement - First Quarter



                                                INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

                                       Condensed Consolidated Statement of Operations (Unaudited)

                                   (Dollars In thousands, except per share amounts or share amounts)


                                                                                                     Three Months Ended March 31,
                                                                                                     ----------------------------

                                                                                                              2016                      2015


    Net sales                                                                                             $189,630                  $201,609

    Cost of goods sold                                                                                     148,914                   161,083

    Gross profit                                                                                            40,716                    40,526

    Operating expenses:

         Selling, general and administrative                                                                18,235                    17,991

         Research & development expenses                                                                       996                     1,174

         Total operating expenses                                                                           19,231                    19,165
                                                                                                            ------                    ------

    Operating income                                                                                        21,485                    21,361

    Interest expense, net                                                                                    1,799                     1,151

    Foreign exchange loss (gain)                                                                              (39)                    2,315

    Income before income taxes                                                                              19,725                    17,895

    Provision for income taxes                                                                               6,883                     5,952

    Net income                                                                                             $12,842                   $11,943
                                                                                                           =======                   =======


    Diluted Earnings Per Participating Share                                                                 $0.66                     $0.55

    Diluted weighted average participating shares outstanding                                           19,430,029                21,501,634

    Dividends paid per share of common stock                                                                 $0.48                     $0.48

    Dividends declared per share of common stock                                                             $0.48                     $0.48

Adjusted EBITDA Reconciliation to Net Income



    (Dollars in thousands)

                                             1Q16         1Q15         2Q15         3Q15          4Q15             2015
                                             ----         ----         ----         ----          ----             ----

    Net Income                                    $12,842      $11,943      $13,603        $5,433        ($4,633)   $26,346

    Interest                                        1,799        1,151        1,403         1,869           3,095      7,518

    Taxes                                           6,883        5,952        6,142         2,628           (945)    13,777

    Depreciation & Amortization                     9,282        9,871       10,761         9,048           8,855     38,535

    EBITDA                                         30,806       28,917       31,909        18,978           6,372     86,176


    Adjustments
    -----------

    Non-cash stock compensation (ordinary) *          534          183        1,402           658             180      2,423

    Translation (income) expense                     (39)       2,315          117         2,629         (1,180)     3,881

    Restructuring (income) expense                   (43)           -           -        8,621               -     8,621

    Management transition expense                       -           -           -            -         11,789     11,789

    Specialty Phosphates inventory reserves             -           -           -            -          3,312      3,312

    Revision of 2014 supplier costs                     -           -           -            -          2,000      2,000

    Adjusted EBITDA                               $31,258      $31,415      $33,428       $30,886         $22,473   $118,202
                                                  =======      =======      =======       =======         =======   ========


    Percent of Sales                                16.5%       15.6%       15.4%        15.5%          13.2%     15.0%


    * Not adjusted for in Adjusted EPS

Segment Reporting - First Quarter

The Company reports its operations in three segments: Specialty Phosphates US & Canada, Specialty Phosphates Mexico and GTSP & Other. The primary performance indicators for the chief operating decision maker are sales and EBITDA, with sales presented on a ship-from basis. Sales on a ship-from basis are on the same revenue recognition principle as a ship-to basis and are recognized when delivery has occurred and title and risk of loss passes to the customer. The following table sets forth the historical results of these indicators by segment:




                                          Three Months Ended March 31,   Net Sales
                                          ----------------------------

                                                                    2016               2015 % Change

    Segment Net Sales

    Specialty Phosphates US & Canada                            $136,720           $147,124          (7.1)%

    Specialty Phosphates Mexico                                   40,398             42,220          (4.3)%

    Total Specialty Phosphates                                   177,118            189,344          (6.5)%
                                                                 -------            -------           -----

    GTSP & Other                                                  12,512             12,265            2.0%

    Total                                                       $189,630           $201,609          (5.9)%
                                                                ========           ========           =====


    Segment EBITDA

    Specialty Phosphates US & Canada                             $17,611            $21,949

    Specialty Phosphates Mexico                                   13,158              7,973

    Total Specialty Phosphates                                    30,769             29,922
                                                                  ------             ------

    GTSP & Other                                                      37            (1,005)

    Total                                                        $30,806            $28,917
                                                                 =======            =======


    Segment EBITDA %  of net sales

    Specialty Phosphates US & Canada                               12.9%             14.9%

    Specialty Phosphates Mexico                                    32.6%             18.9%

    Total Specialty Phosphates                                     17.4%             15.8%
                                                                    ----               ----

    GTSP & Other                                                    0.3%            (8.2)%

    Total                                                          16.2%             14.3%
                                                                    ====               ====


    Depreciation and amortization expense

    Specialty Phosphates US & Canada                              $6,191             $6,939

    Specialty Phosphates Mexico                                    2,192              2,098

    Total Specialty Phosphates                                     8,383              9,037
                                                                   -----              -----

    GTSP & Other                                                     899                834

    Total                                                         $9,282             $9,871
                                                                  ======             ======

Price / Volume - First Quarter

The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. The current quarter selling price dollar variance is derived from the current quarter year to date selling price dollar variance less the previous quarter year to date selling price dollar variance. The selling price dollar variance is then divided by the prior period sales dollars to calculate the percentage change. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

The following tables illustrate for the three months ended March 31, 2016 the percentage changes in net sales by reportable segments and by Specialty Phosphates product lines compared with the same period of the prior year, including the effect of selling price and volume/mix changes upon revenue:




    Reportable Segments                 Price        Volume/Mix          Total
    -------------------                -----         ----------         -----

    Specialty Phosphates US & Canada            1.2%            (8.3)%         (7.1)%

    Specialty Phosphates Mexico               (2.9)%            (1.4)%         (4.3)%

    Total Specialty Phosphates                  0.3%            (6.8)%         (6.5)%

    GTSP & Other                             (16.6)%             18.6%           2.0%

    Total                                     (0.7)%            (5.2)%         (5.9)%
                                               =====              =====           =====




    Specialty Phosphates Product Lines  Price        Volume/Mix          Total
    ---------------------------------- -----         ----------         -----

    Specialty Ingredients                       1.2%            (7.7)%         (6.5)%

    Food & Technical Grade PPA                (1.7)%            (2.6)%         (4.3)%

    STPP & Detergent Grade PPA                (1.9)%            (8.9)%        (10.8)%

Summary Cash Flow Statement



                                                                          INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

                                                                Condensed Consolidated Statements of Cash Flows (Unaudited)

                                                                                   (Dollars in thousands)


                                                                                                                            Three Months Ended March 31,
                                                                                                                            ----------------------------

                                                                                                                                     2016                     2015

    Cash flows (used for) provided from operating activities

         Net income                                                                                                               $12,842                  $11,943

         Adjustments to reconcile net income to net cash (used for)

         provided from operating activities:

              Depreciation and amortization                                                                                         9,282                    9,871

              Amortization of deferred financing charges                                                                              168                      143

              Deferred income tax provision                                                                                             -                     107

              Share-based compensation                                                                                                (9)                     183

         Changes in assets and liabilities:

             Increase in accounts receivable                                                                                     (12,170)                 (9,930)

             Decrease in inventories                                                                                                6,072                    8,268

             Increase in other current assets                                                                                     (9,617)                 (2,719)

             Increase (decrease) in accounts payable                                                                                6,310                 (16,615)

             Decrease in other current liabilities                                                                               (14,388)                   (429)

             Changes in other long-term assets and liabilities                                                                    (1,564)                   1,271

                    Net cash (used for) provided from operating activities                                                        (3,074)                   2,093

    Cash flows used for investing activities:

          Capital expenditures                                                                                                    (8,024)                 (5,911)

                   Net cash used for investing activities                                                                         (8,024)                 (5,911)

    Cash flows provided from financing activities:

         Proceeds from exercise of stock options                                                                                        9                      189

         Long-term debt borrowings                                                                                                 23,000                   70,000

         Long-term debt repayments                                                                                                (5,001)                 (1,001)

         Excess tax (deficiency) benefit from exercise of stock options                                                             (331)                     273

         Common stock repurchases and restricted stock forfeitures                                                                      -                (34,316)

         Dividends paid                                                                                                           (9,256)                (10,198)

                  Net cash provided from financing activities                                                                       8,421                   24,947

    Effect of foreign exchange rate changes on cash and cash equivalents                                                              206                     (90)

    Net change in cash                                                                                                            (2,471)                  21,039

    Cash and cash equivalents at beginning of period                                                                               17,905                   36,207

    Cash and cash equivalents at end of period                                                                                    $15,434                  $57,246
                                                                                                                                  =======                  =======

Summary Balance Sheets



                                                                   INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

                                                              Condensed Consolidated Balance Sheets (Unaudited)

                                                                            (Dollars In thousands)


                                                                                                                March 31,         December 31,
                                                                                                                             2016                 2015

    ASSETS

    Current assets:

         Cash and cash equivalents                                                                                        $15,434              $17,905

         Accounts receivable, net                                                                                          91,888               79,743

         Inventories                                                                                                      166,610              172,667

         Assets held for sale                                                                                                 563                    -

         Other current assets                                                                                              33,065               23,514

                   Total current assets                                                                                   307,560              293,829

    Property, plant and equipment, net                                                                                    199,360              199,494

    Goodwill                                                                                                               84,373               84,373

    Intangibles and other assets, net                                                                                      88,821               90,522

                   Total assets                                                                                          $680,114             $668,218
                                                                                                                         ========             ========

    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current liabilities:

         Current portion of long-term debt                                                                                 $4,001               $4,002

         Accounts payable, trade and other                                                                                 43,346               36,898

         Other current liabilities                                                                                         48,735               63,204

                   Total current liabilities                                                                               96,082              104,104

    Long-term debt                                                                                                        225,834              207,665

    Other long-term liabilities                                                                                            22,175               23,189

                   Total stockholders' equity                                                                             336,023              333,260

                   Total liabilities and stockholders' equity                                                            $680,114             $668,218
                                                                                                                         ========             ========

Additional Information

Net debt is a supplemental financial measure that is not required by, or presented in accordance with, USGAAP. The Company believes net debt is helpful in analyzing leverage and as a performance measure for purposes of presentation in this release. The Company defines net debt as total long-term debt (including any current portion) less cash and cash equivalents.

EBITDA is a supplemental financial measure that is not required by, or presented in accordance with, USGAAP. The Company believes EBITDA is helpful in analyzing the cash flow generating capability of the business and as a performance measure for purposes of presentation in this release. The Company defines EBITDA as net income (loss) before interest, taxes, depreciation and amortization.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/innophos-holdings-inc-reports-first-quarter-2016-results-300258787.html

SOURCE Innophos Holdings, Inc.